Bimodal Release Two-In-One Clonazepam Matrix Lozenge Tablets for Managing Anxiety-Related Disorders: Formulation, Optimization and In Vivo Evaluation
Clonazepam (CLZ), an antipsychotic drug reported for its efficiency in managing anxiety-related disorders, is being marketed only as conventional tablets. Some patients have abstention to swallow the conventional tablets; therefore, the proposed study was aimed at developing a buccal lozenge tablet...
Saved in:
Main Authors: | , , , |
---|---|
Format: | Book |
Published: |
MDPI AG,
2022-07-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
LEADER | 00000 am a22000003u 4500 | ||
---|---|---|---|
001 | doaj_148d2b3027d64198ab2166f565568cd9 | ||
042 | |a dc | ||
100 | 1 | 0 | |a Eman Gomaa |e author |
700 | 1 | 0 | |a Sami El Deeb |e author |
700 | 1 | 0 | |a Adel Ehab Ibrahim |e author |
700 | 1 | 0 | |a Mennatullah M. Faisal |e author |
245 | 0 | 0 | |a Bimodal Release Two-In-One Clonazepam Matrix Lozenge Tablets for Managing Anxiety-Related Disorders: Formulation, Optimization and In Vivo Evaluation |
260 | |b MDPI AG, |c 2022-07-01T00:00:00Z. | ||
500 | |a 10.3390/scipharm90030043 | ||
500 | |a 2218-0532 | ||
500 | |a 0036-8709 | ||
520 | |a Clonazepam (CLZ), an antipsychotic drug reported for its efficiency in managing anxiety-related disorders, is being marketed only as conventional tablets. Some patients have abstention to swallow the conventional tablets; therefore, the proposed study was aimed at developing a buccal lozenge tablet by direct compression of two types of optimized granules. Conazepam's water solubility was first enhanced by a solid dispersion technique for a fast and better dissolution of type 1 granules, while the impact of gelling polymers was investigated on controlled-release type 2 granules. The optimized formulae met the acceptable pharmacopeial limits for tablets' evaluation. A differential scanning calorimetry study revealed the compatibility between the drug and used excipients. All formulae gave a burst release of CLZ in the first hour of investigation, followed by a sustained release over 24 h. The formula that showed the highest prolonged in vitro release (99.0 + 0.1%), following the Higuchi diffusion model (R<sup>2</sup> = 0.99), was then selected for further study. The formula succeeded in controlling the induced stress in a rat model with a significant impact on the behavioral tests throughout the experiment. The results were further confirmed by a pharmacokinetic study that showed a significant increase in Cmax, Tmax, and AUC (1.5, 2, and 3.9 folds), respectively, compared to oral suspension. The newly proposed delivery system has proven a better efficacy with a reduced dosing frequency. | ||
546 | |a EN | ||
690 | |a Clonazepam | ||
690 | |a buccal lozenge tablets | ||
690 | |a bimodal behavior | ||
690 | |a pharmacokinetic | ||
690 | |a Pharmacy and materia medica | ||
690 | |a RS1-441 | ||
655 | 7 | |a article |2 local | |
786 | 0 | |n Scientia Pharmaceutica, Vol 90, Iss 3, p 43 (2022) | |
787 | 0 | |n https://www.mdpi.com/2218-0532/90/3/43 | |
787 | 0 | |n https://doaj.org/toc/0036-8709 | |
787 | 0 | |n https://doaj.org/toc/2218-0532 | |
856 | 4 | 1 | |u https://doaj.org/article/148d2b3027d64198ab2166f565568cd9 |z Connect to this object online. |